Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Difelikefalin (Korsuva) is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
• Two studies focusing on the safety and efficacy of difelikefalin, without direct comparison to other interventions, were examined. These studies highlight the significant improvement in pruritus symptoms among patients with chronic kidney disease undergoing hemodialysis. Improvement is notably reflected in enhanced scores on the Worst Itch Numeric Rating Scale and 5-D itch score, indicating substantial alleviation of symptoms.
• Alongside these benefits, an increase in adverse reactions has been observed. Side effects, described as mild, include nausea, vomiting, dizziness, and diarrhea, suggesting a delicate balance between symptom relief and potential side effects.
• Both studies specifically target adult patients undergoing hemodialysis with moderate-to-severe CKD-aP. This subgroup focus directs Korsuva's utilization towards individuals most likely to benefit from targeted kappa-opioid receptor therapy due to their specific condition contributing to pruritus.
• It is highlighted that difelikefalin has been recognized as the first intervention for CKD-aP in adult HD patients, marking a pioneering milestone within this therapeutic area.